GlassScriptPhysician profile
Mohamadali Amlani
NPI 1154385870
$7,999.61
in general payments reported to CMS, 2019-2025
34 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $475 · 2021: $1,213 · 2022: $1,192 · 2023: $1,281 · 2024: $1,293 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,701.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,463.33 | 2019-2025 | |
| Amgen INC. | $1,396.51 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $603.23 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $575.42 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $485.65 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $340.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.56 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $321.65 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $295.30 | 2019-2025 | Opsumit, Uptravi |
| Boston Scientific Corporation | $274.17 | 2019-2025 | Watchman Flx, Sq-Rx Pulse Generator, Emblem Mri S-Icd |
| Astellas Pharma US INC | $262.32 | 2019-2020 | |
| Abbott Laboratories | $161.82 | 2019-2024 | Cardiomems |
| Kestra Medical Technology Services, INC. | $141.48 | 2022-2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $135.30 | 2022-2025 | |
| Esperion Therapeutics, INC. | $127.31 | 2020-2024 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $121.61 | 2024 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $108.56 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $106.13 | 2020-2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $97.89 | 2019-2021 | |
| Novo Nordisk INC | $89.28 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Heartflow, INC. | $81.53 | 2023 | Ffrct |
| Astrazeneca Pharmaceuticals LP | $77.22 | 2019-2025 | Wainua |
| Medtronic, INC. | $76.46 | 2022-2025 | Corevalve Evolut R |
| Medtronic Vascular, INC. | $71.27 | 2019 | |
| Bridgebio Pharma, INC. | $52.60 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $49.53 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $45.87 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $26.35 | 2022 | |
| Philips North America LLC | $19.33 | 2024 | (Ck4) Mcot |
| Corcept Therapeutics | $19.24 | 2025 | Korlym |
| Teleflex LLC | $19.01 | 2023 | Manta |
| Cordis US Corp. | $16.33 | 2025 | Mynx Control |
| Biotronik INC. | $14.62 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamadali Amlani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.